Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) – Equities researchers at Leerink Partnrs upped their Q3 2023 EPS estimates for Ionis Pharmaceuticals in a research report issued on Monday, September 18th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings per share of ($0.85) for the quarter, up from their previous […]
Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Free Report) have received a consensus recommendation of “Hold” from the nine research firms that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to […]
StockNews.com assumed coverage on shares of Ionis Pharmaceuticals (NASDAQ:IONS – Free Report) in a research note published on Thursday morning. The firm issued a hold rating on the stock. Other equities analysts have also recently issued reports about the company. VNET Group reiterated a maintains rating on shares of Ionis Pharmaceuticals in a report on […]
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) – Investment analysts at William Blair cut their Q3 2023 earnings estimates for Ionis Pharmaceuticals in a report issued on Wednesday, August 9th. William Blair analyst M. Minter now expects that the company will post earnings of ($0.95) per share for the quarter, down from their previous forecast […]
Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) posted its quarterly earnings results on Wednesday. The company reported $0.60 EPS for the quarter, topping the consensus estimate of ($0.94) by $1.54, reports. The business had revenue of $188.00 million during the quarter, compared to analysts’ expectations of $136.84 million. Ionis Pharmaceuticals had a negative net margin […]